Manufacturing News of Note—Novartis to have Cell Therapies make Kymriah in Australia; Piramal Pharma expands API plant in Canada | Fierce Pharma
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy | Journal of Law, Medicine & Ethics | Cambridge Core
Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon - Cytotherapy
NICE backs Novartis' Adakveo via special channel despite 'high uncertainty' about cost, long-term efficacy | Fierce Pharma
CAR T-cell treatment pathway: From patient identification to long-term management - touchONCOLOGY
Non-viral precision T cell receptor replacement for personalized cell therapy | Nature
ASCO: Gilead's Kite soars over Novartis' CAR-T turf with Tecartus win in type of leukemia | Fierce Pharma
Gene Therapy Reviews Return To US FDA Advisory Committee Schedule :: Pink Sheet
FDA Introductory Remarks Tisagenlecleucel Novartis Pharmaceuticals Corporation
FDA Panel Unanimously Recommends Approval for Novartis' CAR-T Therapy CTL019
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology
ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah | Fierce Pharma
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas | Nature Medicine
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Frontiers | Manufacturing and Management of CAR T-Cell Therapy in “COVID-19's Time”: Central Versus Point of Care Proposals
FDA Panel Votes Unanimously to Support Leukemia Gene-Therapy Treatment - WSJ
ONCOLOGIC DRUGS ADVISORY COMMITTEE BRIEFING DOCUMENT Tisagenlecleucel (CTL019) for the TREATMENT OF PEDIATRIC AND YOUNG ADULT PA
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
ASCO: Positive trial shows Novartis' Kymriah poised to play catch-up in CAR- T rivalry with Gilead's Yescarta | Fierce Pharma
